Innovative utilization of cell membrane-coated nanoparticles in precision cancer therapy.

Cell membrane-coated nanoparticles (CMNPs) have recently emerged as a promising platform for cancer therapy. By encapsulating therapeutic agents within a cell membrane-derived coating, these nanoparticles combine the advantages of synthetic nanoparticles and natural cell membranes. This review provides a comprehensive overview of the recent advancements in utilizing CMNPs as effective drug delivery vehicles for cancer therapy.

Biomimetic Self-Propelled Asymmetric Nanomotors for Cascade-Targeted Treatment of Neurological Inflammation.

The precise targeted delivery of therapeutic agents to deep regions of the brain is crucial for the effective treatment of various neurological diseases. However, achieving this goal is challenging due to the presence of the blood‒brain barrier (BBB) and the complex anatomy of the brain. Here, a biomimetic self-propelled nanomotor with cascade targeting capacity is developed for the treatment of neurological inflammatory diseases.

Development and validation of an ultra-high sensitive next-generation sequencing assay for molecular diagnosis of clinical oncology.

Dramatic improvements in the understanding of oncogenes have spurred the development of molecular target therapies, which created an exigent need for comprehensive and rapid clinical genotyping. Next-generation sequencing (NGS) assay with increased performance and decreased cost is becoming more widely used in clinical diagnosis. However, the optimization and validation of NGS assay remain a challenge, especially for the detection of somatic variants at low mutant allele fraction (MAF).

[Clinical diagnosis and treatment of primary retroperitoneal schwannoma: a report of 109 cases].

Objective: To evaluate the surgical efficacies of primary retroperitoneal schwannoma (PRS) and analyze its risk factors for survival and recurrence.

Methods: From January 1993 to December 2012, 109 patients diagnosed with primary retroperitoneal schwannoma were treated at our department. And their clinical data were retrospectively analyzed.

Prognostic factors predicting the postoperative survival period following treatment for primary retroperitoneal liposarcoma.

Background: Liposarcomas, which represent 20% of all adult sarcomas, are the most common histological type of malignant soft tissue tumors. The aim of this study was to define the prognostic factors that predict the postoperative survival period for patients with primary retroperitoneal liposarcoma.

Methods: The clinical data and prognoses of 71 patients with primary retroperitoneal liposarcoma who were treated in the General Hospital of the People's Liberation Army of China between January 1, 2000 and December 31, 2007 were retrospectively reviewed and analyzed.

CREPT expression correlates with poor prognosis in patients with retroperitoneal leiomyosarcoma.

Retroperitoneal leiomyosarcomas (LMSs) are rare gynecological malignancies that display poor prognosis and high mortality. Cell cycle-related and expression-elevated protein in tumor (CREPT) is an oncogene that is involved in the regulation of many cell cycle-related proteins. However, its distribution and clinical significance in retroperitoneal LMS remains poorly understood.

[Expression of CD133 in primary retroperitoneal leiomyosarcoma and its relationship with Ki-67].

Objective: To explore the correlation between CD133 and proliferative marker Ki-67 in primary retroperitoneal leiomyosarcoma and evaluate their prognostic values.

Methods: A total of 50 primary retroperitoneal leiomyosarcoma samples were collected at our hospital from January 2000 to December 2012. There were 9 males and 41 females.